Literature DB >> 26193485

Correction: Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Michael Donahoe, Vincent G Valentine, Nydia Chien, Kevin F Gibson, Jay S Raval, Melissa Saul, Jianmin Xue, Yingze Zhang, Steven R Duncan.   

Abstract

Entities:  

Year:  2015        PMID: 26193485      PMCID: PMC4508023          DOI: 10.1371/journal.pone.0133684

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
In the penultimate sentence of the Results section of the Abstract, the plus sign should be a plus-or-minus sign. The correct sentence is: One-year survival of trial subjects was 46±15% vs. 0% among historical controls. In Table 2, spaces are missing before the acronym “PEEP” in the “Pre-Rx O2” and “Post-Rx O2” columns. Please see the correct Table 2 here.
Table 2

Individual Treatment Outcomes.

#Pre-Rx O2 Post-Rx O2 Comments
1FIO2 0.7 PEEP 10FIO2 1.0 PEEP 10Lung function worsened during treatment. Died on day 11 after recurrent MI.
2FIO2 0.7 PEEP 1050% FMDespite improvement, her care was changed to comfort measures only at family request. She was extubated successfully and treated with MS gtts.
315L NC5L NCLess dyspnea and ambulating after treatment. Respiratory function remainedimproved post-treatment. Died suddenly on day 76 (cause uncertain but likely cardiac).
410L NC4L NCLess dyspnea and ambulating after treatment. Respiratory function remained improved post-treatment for >365 days.
5100% FM Bi-level positive pressure by mask5L NCLess dyspnea and ambulating after treatment. AE-IPF relapsed 3 days later and he required intubation and mechanical ventilation. Repeated TPE x 5, with clinical response and was successfully extubated to 5L NC. He insisted on eating but failed swallow study. He elected CMO status and ate, aspirated, and transferred to SNF on MS gtts. Died on day 32.
660% FMRoom AirMuch less dyspnea and ambulating after treatment, and discharged from the hospital. Relapse on day 27 and was treated again with 5x TPE, but did not respond. Died on day 40.
715L NCoxi Room AirGood response but disease recurred 2 d after completion of TPE x 5. Responded again to 6 additional TPE, and discharged to home on room air, where he remained until lung transplantation on day 98.
810L NC3L NCDoing well at home on day 237
915L NCoxi Room AirDischarged and returned to work. Awaiting transplant on day 137.
1060% FMFIO2 0.7 PEEP 10Did not respond to TPE x 5 and rituximab x 1. Prostate cancer (Stage III) diagnosed by needle biopsy after treatment initiated. Support withdrawn on day 15.
1115L NCoxi 1LDischarged to rehabilitation facility. Now at home and doing well on day 96.

Pre and Post are relative to experimental treatment courses (Rx); O2 requirements denoted as that necessary to maintain resting arterial oxygen saturations at ≥93%; MI = myocardial infarction; FM = face mask; NC = nasal cannula; NCoxi = nasal cannula with “oxymizer” reservoir; CMO = comfort measures only; MS gtts = morphine sulfate infusion; TPE = therapeutic plasma exchange; SNF = skilled nursing facility.

Pre and Post are relative to experimental treatment courses (Rx); O2 requirements denoted as that necessary to maintain resting arterial oxygen saturations at ≥93%; MI = myocardial infarction; FM = face mask; NC = nasal cannula; NCoxi = nasal cannula with “oxymizer” reservoir; CMO = comfort measures only; MS gtts = morphine sulfate infusion; TPE = therapeutic plasma exchange; SNF = skilled nursing facility.
  1 in total

1.  Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Authors:  Michael Donahoe; Vincent G Valentine; Nydia Chien; Kevin F Gibson; Jay S Raval; Melissa Saul; Jianmin Xue; Yingze Zhang; Steven R Duncan
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

  1 in total
  1 in total

1.  Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease.

Authors:  Sofia A Moll; Mark G J P Platenburg; Anouk C M Platteel; Adriane D M Vorselaars; Montse Janssen Bonàs; Claudia Roodenburg-Benschop; Bob Meek; Coline H M van Moorsel; Jan C Grutters
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.